Top

BMC Pediatrics

Published in:

Open Access 01-12-2021 | Metastasis | Research article

Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years – a 14-year retrospective single-center study

Authors: Tian Zhi, Wei-Ling Zhang, Yi Zhang, Hui-Min Hu, Dong-Sheng Huang

Published in: BMC Pediatrics | Issue 1/2021

Abstract

Background

The aim of the present study was to summarize the clinical characteristics of in children aged under 3 years and analyze the related factors affecting the prognosis.

Methods

The clinical data of 316 children aged under 3 years (192 males and 124 females) who were admitted to Beijing Tongren Hospital with a pathological diagnosis of HB between May 2005 and May 2019 were analyzed retrospectively. The factors influencing the therapeutic effects on and survival of HB in children with HB were analyzed.

Results

(1) The median age of the enrolled patients was 1.45 years. The most common initial symptom was an abdominal mass (69.0%). The average serum alpha-fetoprotein (AFP) level and platelet count at the initial visit were (97,406.5 ± 5022.8) ng/mL and (418 ± 206) × 10⁹/L, respectively. The epithelial type was the main pathological type (51.9%). According to the PRETEXT preoperative typing system, the most common stage was stage III (57.0%), whereas according to the postoperative Evans staging system, the most common stage was stage IV (41.8%). At the initial visit, 62 cases (19.6%) had vascular invasion, 52 cases (16.5%) had extrahepatic tumor extension, and 20 cases (6.3%) had tumor rupture. Distant metastasis occurred in 132 cases, and the most common metastatic site was the lung (80.3%). The incidence in East China was relatively high (35.4%). (2) The children were followed up until May 2020 (the median follow-up duration was 62 months). It was found that 194 patients had complete remission and 62 had partial remission. The Kaplan–Meier survival analysis showed that the overall survival was 95.3, 88.2, and 79.8% at 1 year, 3 years, and 5 years, respectively, and the event-free survival was 91.1, 83.2, and 75.1%, respectively. The Cox regression analysis showed that AFP level, platelet count, PRETEXT IV, vascular invasion, and distant metastasis at the initial visit were independent risk factors for the prognosis of children with HB (p < 0.05 in all).

Conclusion

The prognosis of HB was correlated with the AFP level, platelet count, PRETEXT staging, vascular invasion, and distant metastasis at initial diagnosis.

Allan BJ, Parikh PP, Diaz S, et al. Predlctors of survival and incidence of hepatoblastoma in the pediatric population. HPB (Oxford). 2013;15(10):741–6.CrossRef

Ayllon Teran D, Gmez Behran O, Ciria Bru R, et al. Efficacy of neoadjuvant therapy and surgical rescue for locally advancedhep, atoblastomas:10 year sinde.center experience and literature review. World J Gastroenterol. 2014;20(29):l0l37–10143.CrossRef

Waters AM, Mathis MS, Beierle EA. A Synopsis of Pediatric Patients With Hepatoblastoma and Wilms Tumor: NSQIP-P 2012–2016. J Surg Res. 2019;244:338–42.CrossRefPubMed

Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s oncology group. J Clin Oncol. 2011;29(24):3301–6. https://doi.org/10.1200/JCO.2010.29.3837.CrossRefPubMedPubMedCentral

Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014 Feb;26(1):19–28. https://doi.org/10.1097/MOP.0000000000000046.CrossRefPubMed

Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumors of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123–32. https://doi.org/10.1007/s00247-006-0361-5.CrossRefPubMed

Rosito P, Mancini AF, Semeraro M, et al. Malignant primary tumors of the liver in childhood. Pediatr Med Chir. 2002;24(3):200–7.PubMed

Matsunaga T, Sasaki F, Ohira M, Hashizume K, Hayashi A, Hayashi Y, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int. 2003;19(3):142–6. https://doi.org/10.1007/s00383-002-0906-0.CrossRefPubMed

Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, et al. Randomized comparison of cisplatin/vincristine/fluoroumcil and cisplatin/continuous infusion doxombicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer group and the pediatric oncology group. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(14):2665–75. https://doi.org/10.1200/JCO.2000.18.14.2665.CrossRef

10.

Marco Schnater J, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer. 2002;94(4):1111–20. https://doi.org/10.1002/cncr.10282.CrossRefPubMed

11.

Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall’Igna P, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer. 2012;48(10):1543–9. https://doi.org/10.1016/j.ejca.2011.12.011.CrossRefPubMed

12.

Maruyama K, Ikeda H, Koizumil T, et al. Prenatal and postnatal histories of very low birthweight infants who developed hepatoblastoma. Pediatr Int. 1999;41(1):82–9.CrossRefPubMed

13.

Logan G, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):776–9.CrossRef

14.

Hafberg E, Borinstein S, Sophoclis P, et al. Contemporary management of hepatoblastoma. Curr Opinion Organ Transpl. 2019;24(3):113–7. https://doi.org/10.1097/MOT.0000000000000618.CrossRef

15.

Czaudernaa P, Haeberle B, et al. The Children’s hepatic tumors international collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101. https://doi.org/10.1016/j.ejca.2015.09.023.CrossRef

16.

Meyers RL, Maibach R, et al. Risk-stratififi ed staging in paediatric hepatoblastoma: a unififi ed analysis from the Children’s hepatic tumors international collaboration. Lancet Oncol. 2017;18(1):122–31.CrossRefPubMed

17.

Weiling Z, Yi Z, et al. Analysis on the treatment and prognosis of 102 children with hepatoblastoma. China. Pediatr Blood Cancer. 2015;20(6):289–92.

18.

Wang TY, Han Y, Gao YJ, et al. Retrospective Analysis of Childhood Hepatoblastoma in a Single Centre in China. Clin Oncol (Royal College of Radiologists (Great Britain)). 2019;31(7):471–8.CrossRef

19.

Angelico R, Grimaldi C, Gazia C, et al. How Do Synchronous Lung Metastases Influence the Surgical Management of Children with Hepatoblastoma? An Update and Systematic Review of the Literature. Cancers. 2019;11:11.CrossRef

20.

Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment. Transl Pediatr. 2014;3(4):293–9. https://doi.org/10.3978/j.issn.2224-4336.2014.09.01.CrossRefPubMedPubMedCentral

21.

Wang TY, Han YL, Gao YJ, et al. Retrospective Analysis of Childhood Hepatoblastoma in a Single Centre in China. 2019.CrossRef

22.

Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, et al. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol. 2013;37(4):390–5. https://doi.org/10.1016/j.canep.2013.03.004.CrossRefPubMedPubMedCentral

Title: Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years – a 14-year retrospective single-center study
Authors: Tian Zhi
Wei-Ling Zhang
Yi Zhang
Hui-Min Hu
Dong-Sheng Huang
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Metastasis
Published in: BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI: https://doi.org/10.1186/s12887-021-02630-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years – a 14-year retrospective single-center study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The impact of childhood injury and injury severity on school performance and high school completion in Australia: a matched population-based retrospective cohort study

Fluid handling and blood flow patterns in neonatal respiratory distress syndrome versus transient tachypnea: a pilot study

Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity

Concurrent and predictive validity of the infant motor profile in infants at risk of neurodevelopmental disorders

Adherence to treatment in paediatric patients – results of the nationwide survey in Poland

Reminder system for health screening in early childhood – an analysis regarding different social circumstances